The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications
The discovery of the benefits of castration for prostate cancer treatment in 1941 led to
androgen deprivation therapy, which remains a mainstay of the treatment of men with …
androgen deprivation therapy, which remains a mainstay of the treatment of men with …
Bipolar androgen therapy followed by androgen receptor inhibition as sequential therapy for prostate cancer
Inhibition of androgen receptor (AR) signaling has been the mainstay of treatment of
advanced prostate cancer (PCa) for the past 80 years. Combination and sequential AR …
advanced prostate cancer (PCa) for the past 80 years. Combination and sequential AR …
The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations
BA Teply, ES Antonarakis - Expert Review of Clinical …, 2022 - Taylor & Francis
Introduction PARP inhibition in prostate cancer has become a standard-of-care option for
men with metastatic castration-resistant prostate cancer (mCRPC) with deficiency in …
men with metastatic castration-resistant prostate cancer (mCRPC) with deficiency in …
Testosterone therapy in advanced prostate cancer
Androgen deprivation therapy is a mainstay of advanced prostate cancer (PCa) but the
resulting low testosterone levels leave men susceptible to a multitude of adverse effects …
resulting low testosterone levels leave men susceptible to a multitude of adverse effects …
Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
I Caramella, A Dalla Volta, M Bergamini, D Cosentini… - Endocrine, 2022 - Springer
Purpose Whether or not androgen receptor (AR) axis could still be targetable in castration
resistant prostate cancer (CRPC) patients with disease progression to next generation …
resistant prostate cancer (CRPC) patients with disease progression to next generation …
[PDF][PDF] The future of Biploar androgen therapy
K Spencer - pcfa.org.au
Metastatic prostate cancer is initially treated with androgen deprivation therapy (ADT) by
inhibiting the cancer cells growth through blockade of testosterone (androgens). Despite a …
inhibiting the cancer cells growth through blockade of testosterone (androgens). Despite a …